Skip to main content

Table 1 Total joint arthroplasty patient characteristics

From: Bridging therapy for oral anticoagulation increases the risk for bleeding-related complications in total joint arthroplasty

  UFH bridging LMWH bridging LMWH prophylaxis p value
(n = 18) (n = 17) (n = 2494)
Mean age (range) 73 (50–85) 72 (53–82) 70 (32–95) 0.222
Male/female 8/10 8/9 849/1645 0.348
Indication THA (n = 1517)     0.187
 Osteoarthritis 10 6 1334  
 Avascular necrosis 1 2 49  
 Late posttraumatic 2 1 80  
 Inflammatory arthritis 0 0 14  
 Acute fracture 1 0 17
Indication TKA (n = 1012)     <0.001
 Osteoarthritis 4 7 975  
 Avascular necrosis 0 1 2  
 Late posttraumatic 0 0 7  
 Inflammatory arthritis 0 0 16  
Procedure     0.932
 Cemented TKA 4 8 1000  
 Cemented THA 12 8 1233
 Uncemented THA 2 1 151  
 Hybrid THA 0 0 30  
 Resurfacing THA 0 0 80  
Indication for bridging therapy     <0.001
 Mechanical heart valve 15 3   
 Other reason 3 14   
Medication of interest     <0.001
 Anticoagulation 16 13 151  
 Antiaggregants 0 1a 482  
 Combined 2 1 8  
 None 0 2b 1853  
  1. aPatient with in-stent coronary stenosis
  2. bOne patient with history of PE and one patient with AF de novo during operation